MARKET

ARWR

ARWR

Arrowhead Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.15
+2.03
+7.77%
Opening 10:58 04/06 EDT
OPEN
27.22
PREV CLOSE
26.12
HIGH
28.70
LOW
26.75
VOLUME
227.07K
TURNOVER
--
52 WEEK HIGH
73.72
52 WEEK LOW
17.30
MARKET CAP
2.86B
P/E (TTM)
52.35
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARWR stock price target is 61.67 with a high estimate of 81.00 and a low estimate of 29.00.

EPS

ARWR News

More
  • Selloff creating bargains in healthcare - Baird
  • Seeking Alpha - Article · 03/25 17:54
  • Blair likes Incyte in premarket analyst action
  • Seeking Alpha - Article · 03/24 11:53
  • Adapting A Portfolio In A Crisis
  • Seeking Alpha - Article · 03/23 14:44
  • Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR)
  • Insider Monkey · 03/20 18:15

Industry

Biotechnology & Medical Research
+3.77%
Pharmaceuticals & Medical Research
+2.99%

Hot Stocks

Symbol
Price
%Change

About ARWR

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.
More

Webull offers kinds of Arrowhead Pharmaceuticals Inc stock information, including NASDAQ:ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions.